|
EDUCATION |
|
1974-1980 |
Athens University School of Medicine |
|
1980-1983 |
Military non-specialized physician and Senior House Officer (SHO) in Ioannina Univ. Hospital , Greece |
|
1983 - 1989 |
Postgraduate specialist training in surgery at J.W.Goethe-University Hospital in Frankfurt a.M., Germany |
|
|
|
|
1988 |
German Doctorate title (Dr.med) – PhD by JWG-Univ. Frankfurt . |
|
1988 |
Postgraduate Titles: Specialized General Surgeon in Greece . |
|
1990 - Today |
Lecturer, Assistant Professor, Associate Professor of Surgery with emphasis on cancer research at Ioannina University School of medicine
|
|
|
|
|
|
ACADEMIC-RESEARCH ACTIVITIES |
|
1983-1999 |
Conventional clinical research on etiology, carcinogenesis, pathology, and multimodal treatment of gastric cancer and breast cancer. |
|
| Since 2000 |
Conventional single protein-coding genes research. |
|
| |
• High penetrance, very rare, heritable mutations in single genes (BRCA1/2, mismatch-repair, and CDH1 genes) with outsized effects on breast, colorectal and gastric cancer predisposition respectively. Development of novel clinical algorithms for personalized preventive interventions (surgery, surveillance) on these high-risk individuals. |
|
|
• Targeted therapy. Evaluation of safety and efficacy of biologic agents added to chemotherapy, surgery and radiotherapy in the metastatic and adjuvant setting of solid cancers. |
|
| Since 2005 |
Networks-based identification of novel cancer targets . |
|
| |
• Limitations of traditional single-genes research as reflected by suboptimal markers and biologics development and modest results in clinical trials |
|
| |
• Available and emerging evidence of highly complexity and heterogeneity of cancer and recent reveal of complex biological systems which drive tumor initiation and metastases. |
|
|
• These findings urgently guide my current translational research for integration of clinical, genetics, genomics and cancer genomes functional data into causal networks for crucial cancer targets discovery. Predicting underlying DNA changes, and interactions among different cancer cells subpopulations and between these and their microenvironment with cancer phenotypes opens new ways to developing robust biomarkers and efficient biologics. The post cancer genomes ear promises tailored multimodal therapy to specific responsive subsets of patients (personalized medicine). |
|
|
|
|
|
PUBLICATIONS – CITATIONS - LECTURERS |
|
|
Over 153 papers with a total impact factor ~ 1000, > 4400 citations (h=52). |
|
|
Multiple lecturers and keynote presentations in international meetings. scientific |
|
|
Guest speaker, keynote presentations, invited speaker in international meetings. |
|
|
|
|
|
Editorial – Reviewer activity |
|
| Since 1999 |
• Reviewer in many international grants (budgets in up to $11,000, and many high-impact journals. |
|
| Since 2002 |
• Founder and Editor-in-Chief of a non-profit, e-journal ( Gastric & Breast Cancer ). |
|
| |
• Editorial board membership in several Journals. |
|
| Since 2009 |
• Associate editor BMC Ca ncer, section cancer genetics and genomics. |
|
|
|
|
|
POSITIONS |
|
| 2003 |
Representative from Greece in EUR-GAST/EPIC project for gastric cancer in European Union. |
|
| 2006 |
Leader, Translational Research, European Union Network of Excellence (EUNE) for Gastric Cancer |
|
| 2008 |
Leader,
Personalized Genomic Cancer Medicine,
Biobank, Ioannina University, Greece. |
|
| 2009 |
Member of the International Breast Cancer Consensus Conference in Kyoto/Japan and Consensus member in International Gastric Cancer Conference in Krakow, Poland . |
|
